Benralizumab Prevents Recurrent Exacerbations in Patients with Chronic Obstructive Pulmonary Disease: A Post Hoc Analysis
Dave Singh,1 Gerard J Criner,2 Alvar AgustÃ,3 Mona Bafadhel,4 Johan Söderström,5 Gabriela Luporini Saraiva,6 Yue Song,6 Idlir Licaj,7 Maria Jison,6 Ubaldo J Martin,6 Ioannis Psallidas8 1Manchester University NHS Foundation Hospital Trust, the University of Manchester, Manchester, UK; 2Lewis Katz...
Published in: | International Journal of Chronic Obstructive Pulmonary Disease |
---|---|
Main Authors: | , , , , , , , , , , |
Format: | Article in Journal/Newspaper |
Language: | English |
Published: |
Dove Press
2023
|
Subjects: | |
Online Access: | https://www.dovepress.com/benralizumab-prevents-recurrent-exacerbations-in-patients-with-chronic-peer-reviewed-fulltext-article-COPD |
id |
ftdovepress:oai:dovepress.com/85473 |
---|---|
record_format |
openpolar |
spelling |
ftdovepress:oai:dovepress.com/85473 2023-08-20T04:10:07+02:00 Benralizumab Prevents Recurrent Exacerbations in Patients with Chronic Obstructive Pulmonary Disease: A Post Hoc Analysis Singh,Dave Criner,Gerard J AgustÃ,Alvar Bafadhel,Mona Söderström,Johan Luporini Saraiva,Gabriela Song,Yue Licaj,Idlir Jison,Maria Martin,Ubaldo J Psallidas,Ioannis 2023-07-27 text/html https://www.dovepress.com/benralizumab-prevents-recurrent-exacerbations-in-patients-with-chronic-peer-reviewed-fulltext-article-COPD en eng Dove Press info:eu-repo/semantics/altIdentifier/doi/10.2147/COPD.S418944 https://www.dovepress.com/benralizumab-prevents-recurrent-exacerbations-in-patients-with-chronic-peer-reviewed-fulltext-article-COPD info:eu-repo/semantics/openAccess International Journal of Chronic Obstructive Pulmonary Disease Short Report info:eu-repo/semantics/article 2023 ftdovepress https://doi.org/10.2147/COPD.S418944 2023-07-30T17:36:34Z Dave Singh,1 Gerard J Criner,2 Alvar AgustÃ,3 Mona Bafadhel,4 Johan Söderström,5 Gabriela Luporini Saraiva,6 Yue Song,6 Idlir Licaj,7 Maria Jison,6 Ubaldo J Martin,6 Ioannis Psallidas8 1Manchester University NHS Foundation Hospital Trust, the University of Manchester, Manchester, UK; 2Lewis Katz School of Medicine, Temple University, Philadelphia, PA, USA; 3Respiratory Institute (Hospital Clinic), IDIBAPS, CIBERES, Catedra Salud Respiratoria (University of Barcelona), Barcelona, Spain; 4School of Immunology and Microbial Sciences, Faculty of Life Sciences and Medicine, King’s College London, London, UK; 5Late-stage Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden; 6Late-stage Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA; 7Cytel Inc, Cambridge, MA, USA; 8Late-Stage Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UKCorrespondence: Dave Singh, Medicines Evaluation Unit, Langley Building, University Hospital of South Manchester, NHS Foundation Trust, Southmoor Road, Manchester, M23 9QZ, UK, Tel +44 (0)161 946 4073, Email dsingh@meu.org.ukAbstract: Exacerbations in chronic obstructive pulmonary disease (COPD), which tend to occur in clusters and increase with disease severity, come with high societal and economic burdens. Prevention and delay of recurrent exacerbations is an unmet and significant therapeutic need for patients with COPD. GALATHEA (NCT02138916) and TERRANOVA (NCT02155660) were trials assessing efficacy of benralizumab in patients with frequent COPD exacerbations despite treatment. Although these studies found that benralizumab given as an add-on treatment did not significantly reduce annual rates of COPD exacerbations after 56 weeks of treatment, in the following exploratory post hoc analysis of the GALATHEA and TERRANOVA trials we identified a potential responder population in which treatment with benralizumab prevents recurrent COPD ... Article in Journal/Newspaper Terranova Dove Medical Press International Journal of Chronic Obstructive Pulmonary Disease Volume 18 1595 1599 |
institution |
Open Polar |
collection |
Dove Medical Press |
op_collection_id |
ftdovepress |
language |
English |
topic |
International Journal of Chronic Obstructive Pulmonary Disease |
spellingShingle |
International Journal of Chronic Obstructive Pulmonary Disease Singh,Dave Criner,Gerard J AgustÃ,Alvar Bafadhel,Mona Söderström,Johan Luporini Saraiva,Gabriela Song,Yue Licaj,Idlir Jison,Maria Martin,Ubaldo J Psallidas,Ioannis Benralizumab Prevents Recurrent Exacerbations in Patients with Chronic Obstructive Pulmonary Disease: A Post Hoc Analysis |
topic_facet |
International Journal of Chronic Obstructive Pulmonary Disease |
description |
Dave Singh,1 Gerard J Criner,2 Alvar AgustÃ,3 Mona Bafadhel,4 Johan Söderström,5 Gabriela Luporini Saraiva,6 Yue Song,6 Idlir Licaj,7 Maria Jison,6 Ubaldo J Martin,6 Ioannis Psallidas8 1Manchester University NHS Foundation Hospital Trust, the University of Manchester, Manchester, UK; 2Lewis Katz School of Medicine, Temple University, Philadelphia, PA, USA; 3Respiratory Institute (Hospital Clinic), IDIBAPS, CIBERES, Catedra Salud Respiratoria (University of Barcelona), Barcelona, Spain; 4School of Immunology and Microbial Sciences, Faculty of Life Sciences and Medicine, King’s College London, London, UK; 5Late-stage Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden; 6Late-stage Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA; 7Cytel Inc, Cambridge, MA, USA; 8Late-Stage Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UKCorrespondence: Dave Singh, Medicines Evaluation Unit, Langley Building, University Hospital of South Manchester, NHS Foundation Trust, Southmoor Road, Manchester, M23 9QZ, UK, Tel +44 (0)161 946 4073, Email dsingh@meu.org.ukAbstract: Exacerbations in chronic obstructive pulmonary disease (COPD), which tend to occur in clusters and increase with disease severity, come with high societal and economic burdens. Prevention and delay of recurrent exacerbations is an unmet and significant therapeutic need for patients with COPD. GALATHEA (NCT02138916) and TERRANOVA (NCT02155660) were trials assessing efficacy of benralizumab in patients with frequent COPD exacerbations despite treatment. Although these studies found that benralizumab given as an add-on treatment did not significantly reduce annual rates of COPD exacerbations after 56 weeks of treatment, in the following exploratory post hoc analysis of the GALATHEA and TERRANOVA trials we identified a potential responder population in which treatment with benralizumab prevents recurrent COPD ... |
format |
Article in Journal/Newspaper |
author |
Singh,Dave Criner,Gerard J AgustÃ,Alvar Bafadhel,Mona Söderström,Johan Luporini Saraiva,Gabriela Song,Yue Licaj,Idlir Jison,Maria Martin,Ubaldo J Psallidas,Ioannis |
author_facet |
Singh,Dave Criner,Gerard J AgustÃ,Alvar Bafadhel,Mona Söderström,Johan Luporini Saraiva,Gabriela Song,Yue Licaj,Idlir Jison,Maria Martin,Ubaldo J Psallidas,Ioannis |
author_sort |
Singh,Dave |
title |
Benralizumab Prevents Recurrent Exacerbations in Patients with Chronic Obstructive Pulmonary Disease: A Post Hoc Analysis |
title_short |
Benralizumab Prevents Recurrent Exacerbations in Patients with Chronic Obstructive Pulmonary Disease: A Post Hoc Analysis |
title_full |
Benralizumab Prevents Recurrent Exacerbations in Patients with Chronic Obstructive Pulmonary Disease: A Post Hoc Analysis |
title_fullStr |
Benralizumab Prevents Recurrent Exacerbations in Patients with Chronic Obstructive Pulmonary Disease: A Post Hoc Analysis |
title_full_unstemmed |
Benralizumab Prevents Recurrent Exacerbations in Patients with Chronic Obstructive Pulmonary Disease: A Post Hoc Analysis |
title_sort |
benralizumab prevents recurrent exacerbations in patients with chronic obstructive pulmonary disease: a post hoc analysis |
publisher |
Dove Press |
publishDate |
2023 |
url |
https://www.dovepress.com/benralizumab-prevents-recurrent-exacerbations-in-patients-with-chronic-peer-reviewed-fulltext-article-COPD |
genre |
Terranova |
genre_facet |
Terranova |
op_relation |
info:eu-repo/semantics/altIdentifier/doi/10.2147/COPD.S418944 https://www.dovepress.com/benralizumab-prevents-recurrent-exacerbations-in-patients-with-chronic-peer-reviewed-fulltext-article-COPD |
op_rights |
info:eu-repo/semantics/openAccess |
op_doi |
https://doi.org/10.2147/COPD.S418944 |
container_title |
International Journal of Chronic Obstructive Pulmonary Disease |
container_volume |
Volume 18 |
container_start_page |
1595 |
op_container_end_page |
1599 |
_version_ |
1774724082000986112 |